Lumosity
Lumosity operates an adaptive brain training platform serving 120 million registered users across five cognitive domains via freemium and premium subscriptions. The company holds FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic for adults with ADHD.
- Company typePrivate
- Founded2006
- HeadquartersSan Francisco, United States
- Headcount51–100
- GTM typeB2C
- OfferingSoftware
What Lumosity does
Lumosity (operating as Lumos Labs, Inc.) is a consumer cognitive training platform founded in 2005 and headquartered in San Francisco, offering over 40 brain training games organized across five core cognitive domains: memory, speed, attention, flexibility, and problem solving. The platform employs an adaptive algorithm that personalizes game difficulty based on individual user performance and tracks progress via a proprietary metric called the Lumosity Performance Index (LPI), translating 15+ years of cognitive science research into gamified training tasks adapted from laboratory psychology. The company has accumulated 120 million registered users globally across 20 years of operation, with the platform localized into seven languages (English, Spanish, French, German, Japanese, Korean, Portuguese). Cumulative private funding has totaled approximately $67.5 million across Series A through C rounds between 2007 and 2014.
The business operates a product-led, freemium go-to-market model with a free tier offering basic brain training and a paid premium subscription unlocking enhanced features, personalized training, and detailed analytics on a monthly billing cadence. Distribution is digital-first across the proprietary web platform (app.lumosity.com), iOS App Store, and Google Play, with no enterprise or B2B sales motion in the consumer business. Beyond the core product, Lumosity maintains sub-brands including Lumosity Mind (meditation), Figment (creativity), and LumiKids (pediatric cognitive training), each accessible as standalone mobile applications. Pricing is not publicly disclosed but operates on recurring subscription mechanics. Clinical validation of the platform is supported by a randomized 4,715-participant study published in a peer-reviewed journal, in which Lumosity users improved more than an active crossword-puzzle control group on working memory, short-term memory, processing speed, problem solving, fluid reasoning, and overall cognitive function after 10 weeks of 15-minute daily sessions.
In December 2025 the company received FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic for adults with ADHD that demonstrated statistically significant improvements in attention measures and quality of life in a randomized controlled clinical trial of over 500 participants, with high adherence and minimal adverse effects. This regulatory milestone represents Lumosity's strategic extension from a consumer brain-training app into the prescription digital therapeutics channel, where distribution is healthcare-provider-driven and revenue mechanics shift to reimbursement-based pricing rather than monthly consumer subscriptions. The move opens the $1.9 billion global ADHD apps market projected to reach $6.7 billion by 2033, although commercial adoption at inception is minimal given the late-2025 clearance timing.
Lumosity firmographics
Firmographics- Name
- Lumosity
- Legal name
- Lumos Labs, Inc.
- Website
- https://lumosity.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Lumosity operates an adaptive brain training platform serving 120 million registered users across five cognitive domains via freemium and premium subscriptions. The company holds FDA 510(k) clearance for LumosityRx, a prescription digital therapeutic for adults with ADHD.
- Ownership category
- akta.pro rank
Lumosity industry classification
Industry- Product category
- Cognitive Training Software
- NAICS
- Software Publishers (513210), Educational Support Services (611710)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Intelligent Practice & Mastery Learning Platforms (Spaced Repetition, Skill Drills) (EDAFAFAD)
- akta.pro secondary industry
- Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines) (EDAFAKAG)
Keywords
Where Lumosity is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Lumosity business model
Business model- GTM type
- B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Subscription Revenue: Lumosity operates primarily on a subscription model where users pay for premium access to enhanced features, personalized training programs, and detailed analytics. The platform offers both free basic access and paid premium subscriptions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free tier with basic brain training games |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
Lumosity product offering
Product offeringCore offering
Lumosity provides an online cognitive training platform featuring 40+ brain games that target memory, attention, problem-solving, processing speed, and mental flexibility. The platform uses an adaptive algorithm that personalizes difficulty based on individual performance and tracks progress through the proprietary Lumosity Performance Index (LPI). In addition to the consumer-facing app, the company offers LumosityRx, an FDA 510(k)-cleared prescription digital therapeutic for adults with ADHD demonstrated through clinical trials with over 500 participants.
Product overview
Lumosity is a cognitive training platform developed by Lumos Labs offering a suite of brain training products. The core offering is the Lumosity app with over 40 cognitive games organized into categories: Memory, Speed, Attention, Flexibility, Problem Solving, Math, and Word games. The platform adapts to each user's unique cognitive profile using an adaptive algorithm. Additional products include LumosityRx (FDA-cleared prescription digital therapeutic for ADHD), Lumosity Mind (meditation app), Figment (creativity app), and LumiKids (child-focused cognitive training). The company has served over 100 million users across 20 years of operation with products available in 7 languages.
Differentiator
Problem solved
Functional benefit
Brands
- LumosityRx: Prescription digital therapeutic for adults with ADHD, cleared by FDA in December 2025
- Lumosity Mind
- Figment
- LumiKids
Products and services
- Lumosity (Core App) Primary brain training platform offering over 40 cognitive games designed to exercise memory, attention, problem-solving, processing speed, and mental flexibility. Features personalized daily workouts, adaptive difficulty, and progress tracking via the Lumosity Performance Index (LPI). Targeted at individual consumers seeking daily brain training exercises.
- LumosityRx FDA 510(k)-cleared prescription digital therapeutic for adults with ADHD that demonstrated statistically significant improvements in attention measures and quality of life in controlled clinical trials. Distributed via prescription through healthcare providers.
- Lumosity Mind Meditation and mindfulness app available on iOS and Android platforms, complementing the brain training offerings for users seeking relaxation and mental wellness tools.
- Figment A creativity-focused brain training app by Lumosity available on iOS and Android, targeting users interested in creative thinking exercises.
- LumiKids Child-focused app designed to enhance early cognitive and social-emotional skills in young users through age-appropriate interactive games.
Quantifiable outcome
- Lumosity users improved more than control group on assessments of working memory, short-term memory, processing speed, problem solving, fluid reasoning, and overall cognitive function after 10 weeks (5 days/week, 15 min/day)
- +2 more outcomes
Companies that use Lumosity
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Lumosity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature3 records
Lumosity partnerships and signals
Strategic signalScale indicators5 records
Recent moves5 records
Expansion highlights6 records
Lumosity competitors and assessment
Company assessmentDirect peers
- CogniFit: CogniFit offers personalized cognitive training apps and assessments for both consumers and clinical/researchers (including ADHD and special-needs populations), overlapping with both Lumosity's core product and LumiKids/LumosityRx clinical positioning.
- Akili Interactive: Akili's EndeavorRx is an FDA-cleared prescription video-game digital therapeutic (initially for pediatric ADHD) — making it the closest direct peer to LumosityRx in the cognitive-training-as-DTx category, and a category analog for Lumosity's consumer-plus-clinical dual model.
- Peak (Brain Training): Peak (by Brainbow) offers a direct-to-consumer brain-training app with categorized cognitive games (memory, attention, language, problem solving) developed with Cambridge neuroscientists — same product category, similar scientific positioning.
- Elevate: Elevate is a direct competitor to Lumosity's core app: a mobile brain-training subscription product covering memory, attention, and processing speed with daily adaptive workouts for adults.
- NeuroNation: NeuroNation is a science-based brain-training platform with personalized adaptive exercises across multiple cognitive domains, available globally with a freemium subscription model directly comparable to Lumosity.
- Posit Science (BrainHQ): BrainHQ/Posit Science provides scientifically validated computerized cognitive training (auditory/visual processing speed, memory) with clinical-research depth comparable to Lumosity's 15+ years of cognitive research backing.
Broad incumbents
- Calm: Calm is a dominant consumer mental-health/mindfulness subscription that competes with Lumosity Mind for the same wellness-oriented subscriber across overlapping demographics.
- Headspace: Headspace is a broader mental-wellness incumbent whose meditation/mindfulness subscription overlaps directly with Lumosity Mind and competes for the same consumer mental-fitness wallet share.
Emerging players
- Click Therapeutics: Click Therapeutics develops prescription digital therapeutics (including for ADHD) with FDA engagement — comparable to LumosityRx as a next-generation DTx competitor pursuing similar regulatory and payer pathways.
- Big Health: Big Health produces FDA-cleared prescription digital therapeutics (e.g., SleepioRx) for behavioral health — a peer category analog to LumosityRx as another clinical-grade DTx advancing into payer-covered prescription channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks4 records
Key highlights6 records
Customer concentration
Lumosity social profiles
Digital presenceLumosity compliance and trust
Trust signalCompliance1 record
Lumosity financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lumosity leadership team
Management profileNumber of profiles
Profiles5 records
Lumosity subsidiaries and ownership
Company hierarchySubsidiaries1 record
Lumosity funding detail
Funding detailFunding overview
Funding rounds5 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lumosity M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lumosity
What does Lumosity do?
Lumosity provides an online cognitive training platform featuring 40+ brain games that target memory, attention, problem-solving, processing speed, and mental flexibility. The platform uses an adaptive algorithm that personalizes difficulty based on individual performance and tracks progress through the proprietary Lumosity Performance Index (LPI). In addition to the consumer-facing app, the company offers LumosityRx, an FDA 510(k)-cleared prescription digital therapeutic for adults with ADHD demonstrated through clinical trials with over 500 participants.
Is Lumosity a public or private company?
Lumosity is a private company. It is classified as venture growth investor backed and is currently operating.
When was Lumosity founded?
Lumosity was founded in 2006. It employs 51 to 100 people.
Where is Lumosity based?
Lumosity is headquartered in San Francisco, United States, in the North America region.
How does Lumosity make money?
One revenue line is on record: subscription Revenue.
Who are Lumosity's main competitors?
Direct peers on record are CogniFit, Akili Interactive, Peak (Brain Training), Elevate, NeuroNation and Posit Science (BrainHQ). Broad incumbents are Calm and Headspace. Emerging players are Click Therapeutics and Big Health.
Does Lumosity have an API?
No public API is recorded for Lumosity.
What industry is Lumosity in?
Lumosity's product category is Cognitive Training Software. Its primary akta.pro industry code is EDAFAFAD, Intelligent Practice & Mastery Learning Platforms (Spaced Repetition, Skill Drills), with a secondary code of EDAFAKAG, Executive Functioning & Behavioral Support Tools (ADHD, SEL/Behavior Tracking, Routines). Its NAICS code is 513210 and its SIC code is 7372.